Naltrexone/Bupropion Cardiovascular Outcomes Study

PHASE4TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
ObesityCardiovascular Diseases
Interventions
DRUG

Naltrexone HCl/Bupropion HCl ER

Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets

DRUG

Placebo

Naltrexone HCl/bupropion HCl placebo-matching tablets

Trial Locations (139)

Unknown

Alexander City

Auburn

Birmingham

Huntsville

Campe Verde

Chandler

Cottonwood

Fountain Hills

Mesa

Phoenix

Tucson

Fayetteville

Jonesboro

Little Rock

Arvin

Bakersfield

Chino

Downey

El Cajon

Los Alamitos

Los Angeles

Pomona

Sacramento

Santa Ana

Santa Monica

Denver

New London

Stamford

Trumbull

Waterbury

Wilmington

Boca Raton

Bradenton

Brandon

Brooksville

Coral Springs

Cutler Bay

Daytona Beach

Hialeah

Inverness

Jacksonville Beach

Lake Worth

Largo

Miami Lakes

Orlando

Palm Harbor

Pembroke Pines

Ponte Vedra Beach

Sarasota

Stuart

Atlanta

Duluth

Savannah

Honolulu

Pocatello

Blue Island

Chicago

Evanston

Gurnee

Rock Island

Evansville

Topeka

Louisville

Owensboro

Baton Rouge

Bossier City

Lake Charles

Shreveport

Baltimore

Catonsville

Bay City

Saginaw

Port Gibson

Hazelwood

Great Falls

Las Vegas

Linden

Moorestown

Albuquerque

Endwell

Great Neck

Mineola

New York

Saratoga Springs

Staten Island

Asheville

Cary

Charlotte

Durham

Greenville

Hickory

Morehead City

Raleigh

Rocky Mount

Salisbury

Winston-Salem

Canton

Cincinnati

Cleveland

Columbus

Perrysburg

Sandusky

Willoughby

Altoona

Camp Hill

Doylestown

Lansdale

Pittsburgh

Smithfield

Yardley

Charleston

Moncks Corner

Mt. Pleasant

Simpsonville

Bristol

Jackson

Knoxville

Memphis

Arlington

Dallas

Houston

Katy

Kingwood

Palestine

Plano

San Antonio

Bountiful

Murray

Ogden

Orem

South Ogden

West Jordan

West

Richmond

Roanoke

Virginia Beach

Port Orchard

Charleston

Kenosha

Sponsors
All Listed Sponsors
lead

Orexigen Therapeutics, Inc

INDUSTRY